Show simple item record

dc.contributor.authorRondelli, Damiano
dc.contributor.authorGoldberg, Judith D.
dc.contributor.authorIsola, Luis
dc.contributor.authorPrice, Leah S.
dc.contributor.authorShore, Tsiporah B.
dc.contributor.authorBoyer, Michael
dc.contributor.authorBacigalupo, Andrea
dc.contributor.authorRambaldi, Alessandro
dc.contributor.authorScarano, Marco
dc.contributor.authorKlisovic, Rebecca B.
dc.contributor.authorGupta, Vikas
dc.contributor.authorAndreasson, Bjorn
dc.contributor.authorMascarenhas, John
dc.contributor.authorWetzler, Meir
dc.contributor.authorVannucchi, Alessandro M.
dc.contributor.authorPrchal, Josef T.
dc.contributor.authorNajfeld, Vesna
dc.contributor.authorOrazi, Attilio
dc.contributor.authorWeinberg, Rona S.
dc.contributor.authorMiller, Crystal
dc.contributor.authorBarosi, Giovanni
dc.contributor.authorSilverman, Lewis R.
dc.contributor.authorProsperini, Giuseppe
dc.contributor.authorMarchioli, Roberto
dc.contributor.authorHoffman, Ronald
dc.date.accessioned2015-06-03T05:11:18Z
dc.date.available2015-06-03T05:11:18Z
dc.date.issued2014
dc.identifier.bibliographicCitationRondelli, D., Goldberg, J. D., Isola, L., Price, L. S., Shore, T. B., Boyer, M., Bacigalupo, A., Rambaldi, A., Scarano, M., Klisovic, R. B., Gupta, V., Andreasson, B., Mascarenhas, J., Wetzler, M., Vannucchi, A. M., Prchal, J. T., Najfeld, V., Orazi, A., Weinberg, R. S., Miller, C., Barosi, G., Silverman, L. R., Prosperini, G., Marchioli, R. and Hoffman, R. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014. 124(7): 1183-1191. 10.1182/blood-2014-04-572545.en_US
dc.identifier.issn0006-4971
dc.identifier.urihttp://hdl.handle.net/10027/19449
dc.description.abstractFrom 2007 to 2011, 66 patients with primary myelofibrosis or myelofibrosis (MF) preceded by essential thrombocythemia or polycythemia vera were enrolled into a prospective phase 2 clinical trial of reduced-intensity allogeneic hematopoietic stem cell transplantation (AHSCT), Myeloproliferative Disorder Research Consortium 101 trial. The study included patients with sibling donors (n = 32) receiving fludarabine/melphalan (FluMel) as a preparative regimen and patients with unrelated donors (n = 34) receiving conditioning with FluMel plus anti-thymocyte globulin (ATG). Patient characteristics in the 2 cohorts were similar. Engraftment occurred in 97% of siblings and 76% of unrelated transplants, whereas secondary graft failure occurred in 3% and 12%, respectively. With a median follow-up of 25 months for patients alive, the overall survival (OS) was 75% in the sibling group (median not reached) and 32% in the unrelated group (median OS: 6 months, 95% confidence interval [CI]: 3, 25) (hazard ratio 3.9, 95% CI: 1.8,8.9) (P < .001). Nonrelapse mortality was 22% in sibling and 59% in unrelated AHSCT. Survival correlated with type of donor, but not with the degree of histocompatibility match, age, or JAK2V617F status. In patients with MF with sibling donors, AHSCT is an effective therapy, whereas AHSCT from unrelated donors with FluMel/ATG conditioning led to a high rate of graft failure and limited survival. This trial was registered at www.clinicaltrials.gov as #NCT00572897.en_US
dc.description.sponsorshipThis study was supported by National Institutes of Health, National Cancer Institute grant 1 P01 CA108671-01A2 (principal investigator: R.H.).en_US
dc.language.isoen_USen_US
dc.publisherAmerican Society of Hematologyen_US
dc.titleMPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosisen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record